Page 9 - RxExam's Naplex Theory Book Part 2
P. 9

www.pharmacyexam.com                                                                   Krisman


                                 39. ERYTHROPOIESIS AND COLONY STIMULATING AGENTS


               A). Erythropoiesis-Stimulating Agents (ESAs)

               Epoetin alfa                  =  Epogen, Procrit
               Darbepoetin alfa              =  Aranesp
               Epoetin beta methoxy          =  Mircera
               propylene glycol

               B). Colony Stimulating Factors (CSF)

               Filgrastim                    =  Neupogen
               Pegfilgrastim                 =  Neulasta
               Sargramostim                  =  Leukine


                                Dose               Special Notes

                Epoetin alfa    1. Anemia due to   1). Erythropoietin is a glycoprotein which stimulates red blood cell
                (Injection)     Chronic Kidney     production. It is produced in the kidney and stimulates the division
                                Disease:           and differentiation of committed erythroid progenitors in the bone
                                50 to 100 Units/kg  marrow. Epoetin alfa (Epogen, Procrit), a 165 amino acid glycoprotein
                                3 times weekly IV   manufactured by recombinant DNA technology, has the same
                                or SC.             biological effects as endogenous erythropoietin.

                                2. Zidovudine      2). Epoetin alfa (Epogen, Procrit) is indicated for the anemia due to:
                                induced anemia:
                                100 Units/kg 3     a). Chronic Kidney Disease (CKD)
                                times weekly IV or  b). Zidovudine in HIV-infected Patients
                                SC.                c). Chemotherapy in Patients With Cancer
                                                   d). To reduce the need for allogeneic blood transfusions in anemic
                                3. Chemotherapy    patients who are at high risk for perioperative blood loss from elective,
                                induced anemia:    noncardiac, nonvascular surgery.
                                150 Units/kg
                                subcutaneously 3   3). In clinical studies, patients experienced greater risks for death,
                                times per week     serious cardiovascular events, and stroke when administered
                                until completion   erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of
                                of a chemotherapy   13 g/dL and above. Therefore, it is advisable to individualize dosing to
                                course.            achieve and maintain hemoglobin levels within the range of 10 to 12
                                                   g/dL or precisely 11 g/dL.
                                4). Surgery Patients:
                                300 Units/kg per   4). An increased incidence of deep vein thrombosis, serious
                                day SC for 10 days   cardiovascular events and strokes (especially in chronic renal failure
                                before surgery; on   patients), pure red cell aplasia (PRCA), severe anemia, hypertension
                                the day of surgery   and seizure are reported side effects of Epoetin alfa (Epogen, Procrit).
                                and 4 days after
                                surgery.


                                                              8
   4   5   6   7   8   9   10   11   12   13   14